Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Status:
Withdrawn
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in
combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in
patients with sporadic inclusion body myositis (sIBM).
The secondary objectives of the study are:
- To evaluate the efficacy of REGN2477+REGN1033 on the IBM-Functional Rating Scale
(IBM-FRS)
- To evaluate the efficacy of REGN2477+REGN1033 on the sIBM Physical Functioning
Assessment (sIFA)
- To evaluate the safety and tolerability of REGN2477+REGN1033
- To evaluate the effects of REGN2477+REGN1033 on body composition by DXA, including
appendicular lean mass and total fat mass
- To evaluate the efficacy of REGN2477+REGN1033 on measures of muscle performance and
physical function
- To evaluate the efficacy of REGN2477+REGN1033 on patient reported outcome measures
including the fear of falling, falls and near falls, and health-related quality of life
- To evaluate the pharmacokinetic(s) (PK) profile of REGN2477+REGN1033, including
functional REGN2477 and functional REGN1033 concentrations in serum over time
- To evaluate the immunogenicity of REGN2477+REGN1033